GlassScriptPhysician profile
Rachel Murray
NPI 1700259033
$6,685.91
in general payments reported to CMS, 2019-2025
23 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $1,446 · 2023: $967 · 2024: $2,271 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.68 |
| Education | $122.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.94 | 2021-2025 | |
| Dermavant Sciences, INC. | $912.82 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $556.15 | 2022-2024 | Sotyktu |
| Ucb, INC. | $495.16 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $493.98 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $438.03 | 2022-2025 | |
| Galderma Laboratories, L.P. | $425.05 | 2022-2025 | Nemluvio |
| Janssen Biotech, INC. | $423.14 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $409.09 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $229.88 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $219.80 | 2022-2025 | |
| Pfizer INC. | $153.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.48 | 2024-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $126.35 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $117.43 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.67 | 2024-2025 | Otezla, Otezla |
| Biofrontera INC. | $100.52 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Kyowa Kirin, INC. | $60.99 | 2024-2025 | Poteligeo |
| Glaxosmithkline, LLC. | $32.49 | 2024 | Nucala |
| Convatec INC. | $24.89 | 2025 | |
| Organon LLC | $22.48 | 2025 | Vtama |
| Mallinckrodt Hospital Products INC. | $18.49 | 2025 | Acthar |
| Krystal Biotech INC | $18.22 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.